Denosumab: mechanism of action and clinical outcomes
Open Access
- 12 September 2012
- journal article
- review article
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 66 (12), 1139-1146
- https://doi.org/10.1111/ijcp.12022
Abstract
To describe the mechanisms of action of denosumab, a novel antiresorptive agent, contrasting it with other antiresorptive and anabolic osteoporosis treatments. Published papers related to the mechanism of action of approved osteoporosis treatments were sought through MEDLINE searches. Osteoporotic fractures carry a substantial burden of morbidity and mortality, but pharmacotherapy can prevent such fractures in high-risk individuals. Antiresorptive drugs (e.g. bisphosphonates, oestrogen, denosumab) reduce bone turnover by distinct mechanisms. Denosumab, a recently approved therapy, is a fully human monoclonal antibody that binds the cytokine RANKL (receptor activator of NFκB ligand), an essential factor initiating bone turnover. RANKL inhibition blocks osteoclast maturation, function and survival, thus reducing bone resorption. In contrast, bisphosphonates bind bone mineral, where they are absorbed by mature osteoclasts, inducing osteoclast apoptosis and suppressing resorption. These differences in mechanism influence both the onset and reversibility of treatment. Effective pharmacotherapy is necessary for patients at high risk of fracture. Among the treatment options for postmenopausal osteoporosis, there are significant differences in mechanism and dosing. Denosumab acts by a novel mechanism and is administered twice yearly by subcutaneous injection. Identified by Osteoporosis Canada Clinical Practice Guidelines as a first-line agent for treatment of postmenopausal osteoporosis, denosumab represents an important addition to our treatment options.Keywords
This publication has 55 references indexed in Scilit:
- Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extensionJournal of Bone and Mineral Research, 2011
- DenosumabDrugs & Aging, 2011
- 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summaryCMAJ : Canadian Medical Association Journal, 2010
- Impact of Prevalent Fractures on Quality of Life: Baseline Results From the Global Longitudinal Study of Osteoporosis in WomenMayo Clinic Proceedings, 2010
- The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patientsHealth Policy, 2010
- Effect of Osteoporosis Treatment on Mortality: A Meta-AnalysisJournal of Clinical Endocrinology & Metabolism, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisThe New England Journal of Medicine, 2009
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trialBone, 2008
- Estrogen deficiency and bone loss: an inflammatory taleJCI Insight, 2006
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJama-Journal Of The American Medical Association, 2002